'김갑성' 기자의 전체기사
-
텐센트 클라우드 해커톤, 48시간 만에 '사회적 선을 위한 AI' 혁신 프로젝트 17건 탄생시키며…
[ 메디채널 김갑성 기자 ] -- 초대 행사에서 전 세계 개발자들 집결해 텐센트 클라우드의 AI 도구 활용해 생물다양성과 정신건강 분야의 사회적 혁신 주도 선전, 중국 2025년 9월 25일 -- 2025 텐센트 글로벌 디지털 생태계 서밋(2025 Tencent Global Digital Ecosystem Summit)과 함께 개최된 제1회 텐센트 클라우드 해커톤 글로벌 로드쇼 데이(Tencent Cloud Hackathon Global Roadshow Day)가 선전에서 성공적으로 막을 내렸다. 48시간 동안 46명의 개발자로 이루어진 17개 팀이 집중적으로 협력하여 17개의 혁신적인 '사회적 선을 위한 AI(AI for Social Good)' 프로젝트를 구축하며, 기술이 어떻게 의미 있는 사회적 영향을 창출할 수 있는지 보여줬다. 텐센트 지속가능사회가치(Tencent Sustainable Social Value•SSV)와 협력해 열린 이번 행사는 생물 다양성 보존과 정신 건강 지원을 위한 실용적인 AI 솔루션 개발에 초점을 맞췄다. 대회는 AI 코딩, AI 에이전트, 국제 부문 세 가지 트랙으로 구성됐으며,
- 김갑성 기자
- 2025-09-25 09:17
-
NAVER D2SF Invests in GravityLabs, a Healthcare Startup Helping…
[ 메디채널 김갑성 기자 ] - Operates "MoneyWalk", a global healthcare platform achieving more than 30 minutes of daily user engagement - Records 40% of users from overseas markets, aiming to leverage rich health data for the CRO sector - NAVER D2SF has been an early investor in healthcare startups since 2017, with expectations for future collaboration with NAVER's Healthcare project SEONGNAM, South Korea, Sept. 25, 2025 -- NAVER D2SF announced a new investment in GravityLabs, a healthcare startup dedicated to helping users build lasting healthy habits. Gr
- 김갑성 기자
- 2025-09-25 08:00
-
Sky Labs Launches CART BP, a Ring-Type Cuffless Blood Pre…
App-based "Blood Pressure Calendar" enables 24-hour tracking, including nighttime measurements SEOUL, South Korea, Sept. 25, 2025 -- Sky Labs announced the official launch of CART BP, a ring-type personal blood pressure monitor designed for everyday use. Worn on the finger, CART BP enables 24-hour blood pressure monitoring, including during sleep. The device has been approved by Korea's Ministry of Food and Drug Safety (MFDS) and was developed based on the clinically validated technology of CART BP pro, Sky Labs' professional model adopted by hospitals
- 김갑성 기자
- 2025-09-25 06:00
-
ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT
Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingredients, today announced the release of its 2024 Corporate Sustainability Report, available at advancionsciences.com/sustainability. Now in its fourth year of comprehensive sustainability reporting, Advancion continues to strengthen its commitment to transparency, accountabi
- 김갑성 기자
- 2025-09-25 02:40
-
Suvoda and Greenphire complete brand integration with un…
CONSHOHOCKEN, Pa., Sept. 25, 2025 -- Suvoda LLC, a global clinical trial technology company, today announced the completion of its brand integration with Greenphire, unifying both companies under the Suvoda name and brand. Following the successful merger announced in April 2025, the brand integration marks the next step in creating a single company that delivers a comprehensive clinical trial technology platform designed to ease the experience of running and participating in clinical trials. The company now offers a consolidated social media presence on LinkedIn and updated web
- 김갑성 기자
- 2025-09-25 00:01
-
MindHYVE.ai™ Unveils ChironAI™: The World's First AGI-Powered…
NEWPORT BEACH, Calif., Sept. 24, 2025 -- HYVE Labs™ and MindHYVE.ai™ proudly announce the global launch of ChironAI™, an autonomous, next-generation Clinical Decision Support (CDS) system powered by the revolutionary Ava-Healthcare™ AGI reasoning model. Designed from the ground up to transcend the capabilities of conventional AI, ChironAI™ brings unprecedented intelligence, accuracy, and efficiency to frontline healthcare—while reinforcing, not replacing, human clinical judgment. Revolutionary AGI Technology Sets New Standard ChironAI™ operates on the proprietary
- 김갑성 기자
- 2025-09-24 22:40
-
Shaklee® Expands in New Zealand by Acquiring Modere® As…
MIAMI, Sept. 25, 2025 -- Shaklee, a global leader and pioneer in the nutrition and wellness industry, is proud to announce the continued expansion of its international presence through the acquisition of select Modere assets in New Zealand, via a wholly owned subsidiary. This strategic move further strengthens Shaklee's product portfolio and global reach, in addition to securing the product supply chain for these products in the Pacific region. The acquisition includes Modere's rights to all trademarks, patents, and proprietary formulas for all Modere products— most notably for the glo
- 김갑성 기자
- 2025-09-24 21:19
-
Lunit, CellCarta Announce Global Alliance to Expand Acces…
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development. Under the partnership, Lunit's AI pathology solutions will be offered as part of CellCarta's services for global clinical trials, making it easier for pharma sponsors to adopt AI-powered analysis within existing trial workflows. CellCarta operates CAP-a
- 김갑성 기자
- 2025-09-24 21:00
-
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Di…
Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2 Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3 New survey across Asia Pacific and Middle East shows 66% skip routine heart checks and nearly half are unaware of the genetic link to heart disease Experts urge audience to prioritize Lp(a) in cardiovascular strategies, bridging awareness gaps and driving equitable access to testing and care SINGAPORE, Sept. 24, 2025 -- Cardiovascula
- 김갑성 기자
- 2025-09-24 20:21
-
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclus…
SHANGHAI, Sept. 24, 2025 -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., which is a research-led, global pharmaceutical company, for Hengrui's independently developed HER2-targeting ADC, Trastuzumab Rezetecan (SHR-A1811). Under the terms of the agreement, Hengrui has granted Glenmark exclusive rights to develop and commercial
- 김갑성 기자
- 2025-09-24 19:45
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분